eXoZymes (NASDAQ:EXOZ) Issues Quarterly Earnings Results

eXoZymes (NASDAQ:EXOZ) announced its earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, Zacks reports.

eXoZymes Stock Performance

NASDAQ EXOZ traded up $0.20 during trading on Thursday, hitting $5.96. The company’s stock had a trading volume of 4,541 shares, compared to its average volume of 6,214. eXoZymes has a 52 week low of $4.35 and a 52 week high of $18.40. The firm has a market cap of $54.85 million, a P/E ratio of -5.22 and a beta of 2.93. The firm has a 50 day moving average price of $6.67 and a 200 day moving average price of $8.46. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of eXoZymes in a research note on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

eXoZymes Company Profile

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.